Orion Oyj ORNBV

HEL: ORNBV | ISIN: FI0009014377   12/12/2025
60,05 EUR (-1,96%)
(-1,96%)   12/12/2025

9 december 2025 · Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) · Persbericht

8 december 2025 · Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) · Persbericht

5 december 2025 · Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) · Persbericht

3 december 2025 · Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025 · Persbericht

27 november 2025 · 71,498 Orion Corporation A shares converted into B shares · Persbericht

14 november 2025 · Orion receives award for international growth from the President of the Republic of Finland · Persbericht

28 oktober 2025 · Orion Group Interim Report January–September 2025 · Persbericht

24 oktober 2025 · 49,164 Orion Corporation A shares converted into B shares · Persbericht

23 oktober 2025 · Orion and Abzena announce exclusive commercial license for Abzena’s antibody · Persbericht

14 oktober 2025 · Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025 · Persbericht

30 september 2025 · Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal  · Persbericht

30 september 2025 · Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) · Persbericht

26 september 2025 · Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) · Persbericht

19 september 2025 · 80,802 Orion Corporation A shares converted into B shares · Persbericht

20 augustus 2025 · 337,000 Orion Corporation A shares converted into B shares · Persbericht

8 augustus 2025 · Orion Corporation: Managers’ transactions – Juhani Kankaanpää · Persbericht

4 augustus 2025 · Orion Corporation: Managers’ transactions – Satu Ahomäki · Persbericht

21 juli 2025 · Darolutamide receives EU approval in third indication for patients with advanced prostate cancer · Persbericht

18 juli 2025 · Orion Group Half-Year Financial Report January–June 2025 · Persbericht

18 juli 2025 · Orion Corporation’s financial reporting and Annual General Meeting in 2026 · Persbericht

Mijn selecties